ライフサイエンスコーパス: clinical laboratory

1 cine 2018 SCL " which was published by Seoul Clinical Laboratory).

2 the total bilirubin values determined in the clinical laboratory.

3 tional HIV- BDD were measured in 20 BDD in a clinical laboratory.

4 ations for implementation of the method in a clinical laboratory.

5 se activity are periodically isolated by the clinical laboratory.

6 veillance of emerging human pathogens in the clinical laboratory.

7 pplication in biomedical research and in the clinical laboratory.

8 for rapid point-of-care testing of miRNAs in clinical laboratory.

9 or reliable measurement of viral load in the clinical laboratory.

10 lack of active surveillance tests hamper the clinical laboratory.

11 he use of bacteriophage amplification in the clinical laboratory.

12 pin, and mupirocin) performed by the routine clinical laboratory.

13 on time and materials not often found in the clinical laboratory.

14 urdles required to integrate an assay into a clinical laboratory.

15 rtant tool that holds promise for use in the clinical laboratory.

16 with >100 purported disease genes tested in clinical laboratories.

17 patients, is rapidly moving from research to clinical laboratories.

18 California Department of Public Health or at clinical laboratories.

19 abundance proteins is gaining popularity in clinical laboratories.

20 s-three genes that are commonly sequenced in clinical laboratories.

21 eriaceae will likely lead to its adoption by clinical laboratories.

22 ymptomatic donors present many challenges to clinical laboratories.

23 can ideally be performed at resource-limited clinical laboratories.

24 n misidentified by methods used routinely in clinical laboratories.

25 ibility testing methods that are feasible in clinical laboratories.

26 antibiotic treatments outside of centralized clinical laboratories.

27 icrobiota profiling scheme may be adopted by clinical laboratories.

28 r of Enterobacteriaceae commonly isolated by clinical laboratories.

29 producing organisms is a major challenge for clinical laboratories.

30 an accuracy base for routine methods used in clinical laboratories.

31 l ensure that they will both have a niche in clinical laboratories.

32 come a common technique in both research and clinical laboratories.

33 at NGS technology is ready to be deployed in clinical laboratories.

34 ent of diagnostic proteins, such as HbA2, in clinical laboratories.

35 ty hospitals, physicians' offices, and small clinical laboratories.

36 s, including small research laboratories and clinical laboratories.

37 e quantification of proteins is essential in clinical laboratories.

38 try, the standard method for measuring Hb in clinical laboratories.

39 sonnel, thus limiting its use in centralized clinical laboratories.

40 rgically excised specimens in biological and clinical laboratories.

41 r routine colistin susceptibility testing in clinical laboratories.

42 o differences in qPCR amplicon sizes between clinical laboratories.

43 eriaceae carbapenem breakpoints is common in clinical laboratories.

44 e need for health care reform and changes in clinical laboratories.

45 breakpoint revisions are likely to pose for clinical laboratories.

46 ariants that are not routinely identified by clinical laboratories.

47 colistin and polymyxin B) is challenging for clinical laboratories.

48 wide adoption by preclinical researchers and clinical laboratories.

49 sensitive method for the diagnosis of CDI in clinical laboratories.

50 ation method-but is this the right focus for clinical laboratories?

51 With the growth of MS use in clinical laboratories, a reliable MS-based glycolipid ph

52 ens, creating a critical bottleneck blocking clinical laboratories' ability to perform high-sensitivi

53 hree protein biomarkers routinely assayed in clinical laboratories (alanine aminotransferase 1, C-rea

54 Clinical laboratories also need to determine whether and

55 Although morphology and clinical laboratory analysis continue to play an importa

56 among the most common specimens received by clinical laboratories and generate a major share of the

57 tandard approach but is impractical for many clinical laboratories and is often replaced with PCR-bas

58 discordance of variant classification among clinical laboratories and prevents definitive classifica

59 duce the burden of the proposed new rules on clinical laboratories and protect patients' access to st

60 e specimens were tested at the participating clinical laboratories and were all accurately detected b

61 n the challenges of implementing mNGS in the clinical laboratory and address potential solutions for

62 ria LAMP assay was easily implemented in the clinical laboratory and gave similar results to a real-t

63 or infectious diseases currently used in the clinical laboratory and in point-of-care devices are div

64 We identified clinical laboratory and radiological features of ALS4, a

65 Clinical Laboratory and Standards Institute (CLSI) break

66 ed in eight participating laboratories using Clinical Laboratory and Standards Institute (CLSI) guide

67 T were conducted in eight laboratories using Clinical Laboratory and Standards Institute (CLSI) guide

68 We propose to the Clinical Laboratory and Standards Institute that isolate

69 s disease (COVID-19) pandemic has placed the clinical laboratory and testing for SARS-CoV-2 front and

70 tification of Gram-negative organisms in the clinical laboratory and that meaningful performance impr

71 reported BSL-3 laboratory support via their clinical laboratory and/or PHL.

72 Poisson regression identified clinical, laboratory and demographic predictors of eithe

73 complementary predictors of mortality among clinical, laboratory and echocardiographic data, we used

74 Demographic, clinical, laboratory and endoscopic data were collected

75 Subsequent clinical, laboratory and imaging follow-up exams showed

76 al cases were correlated with the results of clinical, laboratory and other imaging studies.

77 We conducted a review of the clinical, laboratory and photographic records to evaluat

78 able for biosensing at the point-of-care, in clinical laboratories, and in research settings.

79 a coli is a pathogen commonly encountered in clinical laboratories, and is capable of causing a varie

80 S/MS methodology in quantitative proteomics, clinical laboratories, and other areas are also discusse

81 iant identification and subtyping methods by clinical laboratories, and the inclusion of small-colony

82 ght contemporary AST challenges faced by the clinical laboratory, and propose some solutions.

83 We investigated clinical, laboratory, and demographic associations with

84 lasma MBG levels and performed comprehensive clinical, laboratory, and echocardiographic assessment i

85 Safety and efficacy were assessed by clinical, laboratory, and echocardiographic assessments

86 ic analysis were used for diagnosis, and the clinical, laboratory, and epidemiological parameters of

87 Demographic, clinical, laboratory, and exposure-risk variables ascert

88 Predictors included longitudinal clinical, laboratory, and histologic data.

89 Clinical, laboratory, and histological reports were anal

90 Clinical, laboratory, and imaging characteristics of chi

91 algorithm (1:1) to account for pretreatment clinical, laboratory, and imaging covariates.

92 Recently developed algorithms including clinical, laboratory, and imaging criteria demonstrated

93 sis: Recently developed algorithms including clinical, laboratory, and imaging criteria demonstrated

94 Retrospective review of the clinical, laboratory, and imaging data of 77 patients.

95 We reviewed clinical, laboratory, and imaging data on 78 patients wi

96 We analyzed correlations between clinical, laboratory, and imaging data with number of ho

97 ence or absence of arthritis on the basis of clinical, laboratory, and imaging findings (excluding DW

98 spectively), whereas some characteristic TTD clinical, laboratory, and imaging findings were absent.

99 Distinct clinical, laboratory, and imaging variables are associat

100 have systematically examined the accuracy of clinical, laboratory, and imaging variables in detecting

101 nd without POAF were compared on a number of clinical, laboratory, and instrumental data.

102 By assessing clinical, laboratory, and mathematical data, we propose

103 Clinical, laboratory, and microbiological data were coll

104 predictors of clinical outcome from among 30 clinical, laboratory, and pharmacokinetic variables.

105 These disorders are marked by clinical, laboratory, and physiologic heterogeneity.

106 iscovery research can be performed utilizing clinical, laboratory, and procedure data obtained during

107 he present study is to evaluate demographic, clinical, laboratory, and prognostic characteristics and

108 Detailed recommendations on the initial clinical, laboratory, and radiographic assessment of ECD

109 Demographic, clinical, laboratory, and radiographic data were analyze

110 Clinical, laboratory, and radiologic data were collected

111 A combination of clinical, laboratory, and sonography findings can be pot

112 Clinical, laboratory, and technical parameters, developm

113 In conclusion, we trust that the clinical, laboratory, and therapeutic criteria for prima

114 t for differences in baseline and changes in clinical, laboratory, and ultrasonic characteristics, HI

115 Clinical, laboratory, and vibration-controlled transient

116 We reviewed available clinical, laboratory, and virologic data from all patien

117 Clinical laboratories are constantly facing challenges t

118 quencing in inherited diseases and oncology, clinical laboratories are evaluating the use of metageno

119 Moreover, the cutoffs used in different clinical laboratories are heterogeneous.

120 Clinical laboratories are now using WGS for pathogen ide

121 rug-resistant Gram-negative infections, many clinical laboratories are unable to perform susceptibili

122 round-times, supporting their utility in the clinical laboratory as routine diagnostic platforms.

123 y Improvement Amendments-approved commercial clinical laboratories, as reported to the Prospective Re

124 ditionally, diagnosis has relied on multiple clinical laboratory assays to assign VWD phenotype.

125 Clinical laboratory assessments generally remained uncha

126 of ivacaftor as assessed by adverse events, clinical laboratory assessments, electrocardiograms, vit

127 has contributed to increasingly unavailable clinical laboratory AST, although gonorrhea is on the ri

128 plicability of the technique to the field of clinical laboratory automation.

129 ytical performance of a LDT developed in our clinical laboratory based on CDC primer sets and four co

130 ct and quantify hemoglobin are important for clinical laboratories, blood banks, and for point-of-car

131 d implementation of sequencing assays in the clinical laboratory, but it has limited throughput, and

132 Use of the EAPCRI recommendations by clinical laboratories can further enhance PCR performanc

133 This study determined the clinical laboratory capabilities of these ETCs.

134 d Drug Administration-cleared test; improved clinical laboratory capacity for colistin susceptibility

135 ETCs were electronically surveyed on clinical laboratory characteristics.

136 exposure risk events (Brucella events) in 7 clinical laboratories (CLs).

137 ty testing by methods readily available in a clinical laboratory compared to agar dilution.

138 unt of species diversity not seen in routine clinical laboratory cultures.

139 When mecA is detected by PCR in the clinical laboratory, current guidelines recommend that t

140 Clinical laboratories currently utilize an array of diff

141 ipants who received study drug by monitoring clinical laboratory data and self-report and direct clin

142 ion, infarct location, coronary anatomy, and clinical laboratory data, with final follow-up through D

143 r of inputs that are readily obtainable from clinical laboratory data.

144 enced the Swedish Dementia Registry with the clinical laboratory database at the Sahlgrenska Universi

145 has all the necessary features suitable for clinical laboratories demanding high-throughput sample p

146 The identification of VISA in the clinical laboratory depends on standard susceptibility t

147 e Aptima ZIKV assay an attractive choice for clinical laboratories detecting ZIKV RNA from serum and

148 he future perspective in introducing MOFs in clinical laboratory diagnostics.

149 le electronic survey, health administrative, clinical, laboratory, drug, and electronic medical recor

150 al samples (n = 531) submitted to a regional clinical laboratory during a 6-month period were tested

151 7 patients with HFpEF and performed detailed clinical, laboratory, ECG, and echocardiographic phenoty

152 rt Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmo

153 ient care by integrating data extracted from clinical, laboratory, echocardiographic, and genetic ass

154 We evaluated a series of demographic, clinical, laboratory, electrocardiographic, and echocard

155 sms to supplement existing techniques in the clinical laboratory, especially in single bacterial colo

156 , fever (temperature >/=38.0 degrees C), and clinical laboratory evaluations for infection (urine cul

157 A positive tuberculin skin test alone among clinical laboratory findings was significantly associate

158 antial changes from baseline in vital signs, clinical laboratory findings, or electrocardiography fin

159 Because of the inconclusive results of both clinical-laboratory findings and ultrasonography, CT ima

160 for inpatient and outpatient procedures, to clinical laboratories for diagnostic tests, and to pharm

161 specimens sent to the Johns Hopkins Hospital clinical laboratory for viral quantitative real-time pol

162 fied as pathogenic or likely pathogenic by a clinical laboratory geneticist blinded to case status.

163 otential to be used outside of hospitals and clinical laboratories, greatly enhancing diagnostic capa

164 Twenty-two (50%) of these ETC clinical laboratories had biosafety level 3 (BSL-3) cont

165 ic disease, routine adoption of FT-IR within clinical laboratories has remained elusive.

166 Clinical laboratories have responded by developing, vali

167 or the detection of carbapenemases; however, clinical laboratories have struggled for years with accu

168 h reduced ejection fraction who had complete clinical, laboratory, health-related quality of life, im

169 uld be less expensive and time-consuming for clinical laboratories; however, this approach would be b

170 e functional class in perspective with other clinical, laboratory, imaging, and hemodynamic parameter

171 iplinary process that incorporates available clinical, laboratory, imaging, and histological features

172 usions and Relevance: Combined findings from clinical, laboratory, imaging, and pathological examinat

173 y 2016 if laboratories choose not to perform Clinical Laboratory Improvement Act (CLIA) default QC.

174 e more familiar clinical requirements of the Clinical Laboratory Improvement Act of 1988 (CLIA '88),

175 DNA/RNA with tumour/normal comparisons in a Clinical Laboratory Improvement Amendments (CLIA) compli

176 selected concentrations were all within the Clinical Laboratory Improvement Amendments (CLIA) criter

177 of N. gonorrhoeae were tested following the Clinical Laboratory Improvement Amendments (CLIA)-approv

178 ated in a multicenter prospective trial in a Clinical Laboratory Improvement Amendments (CLIA)-waived

179 mances of these three commercially available Clinical Laboratory Improvement Amendments (CLIA)-waived

180 Recently, Clinical Laboratory Improvement Amendments (CLIA)-waived

181 in a laboratory that is certified under the Clinical Laboratory Improvement Amendments and authorize

182 Carriers were provided a Clinical Laboratory Improvement Amendments confirmed rep

183 d as clinical diagnostic assays according to Clinical Laboratory Improvement Amendments guidelines.

184 d as clinical diagnostic assays according to Clinical Laboratory Improvement Amendments guidelines.

185 rgeted next-generation sequencing assay in a Clinical Laboratory Improvement Amendments laboratory.

186 nd 10 studies submitted to the FDA and for a Clinical Laboratory Improvement Amendments waiver applic

187 conflicting variant interpretations between Clinical Laboratory Improvement Amendments-approved comm

188 lege of American Pathologists-accredited and Clinical Laboratory Improvement Amendments-certified cli

189 levant time frame, which is performed in our Clinical Laboratory Improvement Amendments-certified Col

190 therapy should have their tumor tested in a Clinical Laboratory Improvement Amendments-certified lab

191 latform for routine use in PHLs according to Clinical Laboratory Improvements Act (CLIA) guidelines f

192 of the gene expression assays were done in a Clinical Laboratory Improvements Amendments certified la

193 Clinical laboratories in areas with resistance levels si

194 rdance was more than twice as frequent among clinical laboratories in ClinVar, a public archive of va

195 settings of endemicity present challenges to clinical laboratories in maintaining competence for accu

196 Additionally, a survey of 17 clinical laboratories in northern California demonstrate

197 10-2011) consecutive E. coli isolates from 5 clinical laboratories in Seattle, Washington, and Minnea

198 Many clinical laboratories in the United States are transitio

199 are one of the most common platform used in clinical laboratories, in particular the class based on

200 urrent methods for pathogen detection in the clinical laboratory include biological culture, nucleic

201 spectrometry technology to most research and clinical laboratories, including those in developing cou

202 plore the use of whole-genome sequencing for clinical laboratory investigations of MRSA molecular epi

203 icrobial susceptibility testing (AST) by the clinical laboratory is paramount to combating antimicrob

204 for Lyme disease at a single hospital-based clinical laboratory located in an area endemic for Lyme

205 dable barrier to introducing such testing in clinical laboratories, making these drugs practically un

206 ions in proteomic, metabolomic, and standard clinical laboratory measurements (clinical labs) from bl

207 fety assessments included adverse events and clinical laboratory measures, assessed in all treated pa

208 well (r = 0.99) with commercially available clinical laboratory method (Roche Diagnostics) to measur

209 Application of this technology as a clinical laboratory method has evolved from the identifi

210 granular lymphocyte populations by standard clinical laboratory methods (flow cytometry, examination

211 zolid in 2 cases led to a review of standard clinical laboratory methods for susceptibility determina

212 In clinical laboratories, most widely used AST methods are

213 Large hospital-based clinical laboratories must be prepared to rapidly invest

214 Animal and Plant Health Inspection Service, clinical laboratories must be proficient at rapidly reco

215 rologically reactive in National Centers for Clinical Laboratories (NCCL), of which 179 were sequence

216 se assays have been performed in centralized clinical laboratories necessitating specimen transport a

217 l identification becomes more commonplace in clinical laboratories, one can expect to see changes in

218 risk of progressive liver disease, based on clinical, laboratory, or imaging findings.

219 eiving mechanical ventilation, those without clinical, laboratory, or radiologic evidence of bacteria

220 ft ventricular ejection fraction (LVEF), and clinical laboratory parameters in all treated patients.

221 The clinical, laboratory parameters, etiology of liver cirrh

222 outcomes included adverse events (AEs), and clinical/laboratory parameters.

223 stin resistance is currently challenging for clinical laboratories, particularly given the absence of

224 ased recommendations that assist clinicians, clinical laboratories, patients and policymakers in deci

225 ue to assay incubation periods and a lack of clinical laboratories performing these tests.

226 lignment program with several advantages for clinical laboratories performing virus sequencing compar

227 Clinical laboratories play a key role in reducing this b

228 and Laboratory Standards Institute and Good Clinical Laboratory Practices guidelines for evaluating

229 he present study is to evaluate demographic, clinical, laboratory, prognostic characteristics and out

230 Statistical analyses were performed of the clinical, laboratory, radiologic image, medical treatmen

231 s, a repository of socioeconomic/geographic, clinical, laboratory, radiological, and genomic data fro

232 Quantitative immunoassay tests in clinical laboratories require trained technicians, take

233 MALDI-MSI implementation in clinical laboratories requires the ability to ensure met

234 The majority had worked in Sierra Leone in clinical, laboratory, research, and other roles.

235 nternational Consortium for Harmonization of Clinical Laboratory Results to coordinate harmonization

236 Serologic methods are an important part of a clinical laboratory's portfolio of severe acute respirat

237 s with workload and understaffing that other clinical laboratory sections have addressed with automat

238 pandemic has posed formidable challenges for clinical laboratories seeking reliable laboratory diagno

239 he use of real-time PCR in a quality assured clinical laboratory setting can be sensitive to low-leve

240 DDs requiring rapid therapeutic actions in a clinical laboratory setting.

241 Eight large clinical laboratories, seven from the United States and

242 These data reveal several factors that clinical laboratories should consider prior to the imple

243 Collaboration among clinical laboratory staff, health professionals, and law

244 nded by the different methods recommended by Clinical Laboratory Standards Institute and Internationa

245 Based on POCT12-A3, the Clinical Laboratory Standards Institute standard for hos

246 Q was observed across various assay kits and clinical laboratories, suggesting that intrinsic molecul

247 ed in hypertrophic cardiomyopathy than among clinical laboratories, suggesting that optimal genetic t

248 cated that their hospital would also provide clinical laboratory support for patient care.

249 e profile was in agreement with the original clinical laboratory susceptibility profile, and the toxi

250 We identified clinical, laboratory, systemic, and radiologic features

251 correlation with standard spectrophotometric clinical laboratory techniques was found.

252 r was associated with solvent exposure among clinical laboratory technologists and technicians (HR, 2

253 Clinical laboratories test for extended-spectrum beta-la

254 Prion-specific assays used in clinical laboratory testing are currently limited to two

255 es and provide the foundation for developing clinical laboratory testing strategies to guide therapeu

256 th new-onset overweight or obesity underwent clinical laboratory testing, including oral glucose tole

257 Although 77 standard clinical laboratory tests and 263 plasma proteins could

258 Clinical laboratory tests are now being prescribed and m

259 ed using metabolomics, advanced imaging, and clinical laboratory tests in addition to family/medical

260 Clinical laboratory tests of thyroid function (including

261 and neurological examinations, vital signs, clinical laboratory tests, cerebrospinal fluid laborator

262 s and protocols to establish traceability of clinical laboratory tests, have been established and con

263 a were good general health, measured through clinical laboratory tests, medical history, and physical

264 fety measures included adverse events (AEs), clinical laboratory tests, vital signs, electrocardiogra

265 otes and electrocardiograms, procedures, and clinical laboratory tests.

266 ng binding to streptavidin, are used in many clinical laboratory tests.

267 Analyses were conducted in a clinical laboratory that performs DNA sequencing.

268 ONT sequencing is an attractive platform for clinical laboratories to adopt due to its low cost, rapi

269 centers has led to an increasing demand for clinical laboratories to assist with product sterility t

270 Based on these data, we urge clinical laboratories to be aware of the variable result

271 ssays (EIAs) are the primary methods used by clinical laboratories to detect enteric bacterial pathog

272 strate the potential of the MinION device in clinical laboratories to fully characterize the epidemic

273 virology laboratory became one of the first clinical laboratories to offer testing for severe acute

274 ith the trend of moving molecular tests from clinical laboratories to on-site testing, there is a nee

275 ntibody detection systems enable high-volume clinical laboratories to perform syphilis screening at a

276 Immunoassays have been used for decades in clinical laboratories to quantify proteins in serum and

277 practice by providing a firm foundation for clinical laboratories to set appropriate cutoffs.

278 methodology that will enable hospital-based clinical laboratories to support cefepime MIC-based dosi

279 A validation study was performed in a single clinical laboratory to determine the accuracy of the mCI

280 itoring (SRM/MRM) mass spectrometry into the clinical laboratory to facilitate clinical proteogenomic

281 It is important for the clinical laboratory to interpret the molecular findings

282 asingly recognized as an enteric pathogen as clinical laboratories transition to culture-independent

283 e well suited to the increasing research and clinical laboratories undertaking exome sequencing, part

284 V assays, which are performed in centralized clinical laboratories using single-plexed assays with bu

285 elated serious adverse events, or changes in clinical laboratory values or vital signs occurred durin

286 Adverse events, clinical laboratory values, and electrocardiograms were

287 oteins, metabolites, cytokines, microbes and clinical laboratory values, correlate with age.

288 Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 33

289 Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-erenum

290 We prospectively characterized the clinical, laboratory, virologic and immunologic features

291 ay demonstrated correlation with traditional clinical laboratory VWF assays.

292 Laboratory Improvement Amendments-certified clinical laboratory, we quantified digital pathology fea

293 s will provide valuable information to other clinical laboratories who are actively developing SARS-C

294 With this approach, the clinical laboratory will be asked to select what AST met

295 d tumor samples underwent WES in a certified clinical laboratory with genetic results categorized on

296 of human bacterial pathogens in real time in clinical laboratories, with little specialist training r

297 on of clinically important microorganisms in clinical laboratories without any preanalysis preparativ

298 analytical tool for diagnosis of HIT in the clinical laboratory, without perturbing the existing dia

299 aerobic actinomycetes isolates under routine clinical laboratory working conditions over a 6-month pe

300 As clinical laboratories worldwide use calibrators traceabl